Recent Updates
Recently added Catalysts

tenecteplase

Phase 2

Myocardial Infarction | Small molecule | Cardiovascular |Eli Lilly and Company|Last Updated: May 19, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment300
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00121446Which Therapy for Acute Heart Attacks? (The WEST Study)PHASE2 COMPLETED 300Jul 1, 2003 -May 19, 201716 Canada
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
composite of 6 elements defined by: death
recurrent myocardial infarction
heart failure
cardiogenic shock
refractory ischemia
major ventricular arrhythmia
Secondary Endpoints
90 and 180 minute ECG ST resolution
QRS determined infarct size at discharge/day 7
CK infarct size determined by area under the curve or peak CK-MB
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
tenecteplaseDRUG -
enoxaparinDRUG -
clopidogrelDRUG -
percutaneous coronary interventionPROCEDURE -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * Male or non-pregnant female patients aged \>18 years * Patients with symptoms presumed secondary to STEMI lasting at least 20 minutes and accompanied by ECG evidence \>2 mm of ST elevation in 2 or more contiguous precordial leads or in 2 or more limb leads;or \> 1mm ST elevati...

Countries:Canada
Unlock Eligibility Criteria